Skip to main content
Premium Trial:

Request an Annual Quote

RXi Closes Acquisition of Apthera

Premium

RXi Pharmaceuticals said this week that it has closed its acquisition of peptide immunotherapy firm Apthera.

As previously announced, RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one (GSN 3/31/2011). Among Apthera's assets is the phase II breast cancer treatment NeuVax.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more